(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 November 2021 (04.11.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/219849 A1

(51) International Patent Classification:

C07D 401/06 (2006.01)	*C07D 471/04* (2006.01)
C07D 401/14 (2006.01)	*C07D 487/04* (2006.01)
C07D 403/06 (2006.01)	*C07D 491/048* (2006.01)
C07D 403/14 (2006.01)	*C07D 491/107* (2006.01)
C07D 405/14 (2006.01)	*A61K 31/4427* (2006.01)
C07D 409/14 (2006.01)	*A61P 29/00* (2006.01)
C07D 413/14 (2006.01)	*A61P 35/00* (2006.01)
C07D 417/14 (2006.01)	*A61P 37/00* (2006.01)

(21) International Application Number:
PCT/EP2021/061401

(22) International Filing Date:
30 April 2021 (30.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/EP2020/062103
30 April 2020 (30.04.2020) EP

(71) Applicant: **IDORSIA PHARMACEUTICALS LTD** [CH/CH]; Hegenheimermattweg 91, 4123 Allschwil (CH).

(72) Inventors: **ALLEMANN, Oliver**; c/o Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil (CH). **CAROFF, Eva**; c/o Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil (CH). **CHAVANTON-ARPEL, Alexia**; c/o Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil (CH). **CROXFORD, Andrew**; c/o Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil (CH). **HUBLER, Francis**; c/o Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil (CH). **JACOB, Loïc**; c/o Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil (CH). **MEYER, Emmanuel**; c/o Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil (CH). **RICHARD-BILDSTEIN, Sylvia**; c/o Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*

WO 2021/219849 A1

(54) Title: AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS

(57) Abstract: The present invention relates to compounds of Formula (I), their synthesis and use as CCR6 receptor modulators for the treatment or prevention of various diseases, conditions or disorders.



(I)